Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients

The presence of comutations (co-mut+) in DNA damage response and repair (DDR) pathways was associated with improved survival for immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). However, it remains unknown whether co-mut+ status could be a predictive biomarker for imm...

Full description

Bibliographic Details
Main Authors: Anning Xiong, Wei Nie, Yan Zhou, Changhui Li, Kai Gu, Ding Zhang, Shiqing Chen, Fengcai Wen, Hua Zhong, Baohui Han, Xueyan Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
DDR
ctDNA = circulating tumor DNA
atezolizumab
predictive biomarker
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.708558/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.708558/full

Similar Items